

# Monica Verdoia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/720995/publications.pdf>

Version: 2024-02-01

184  
papers

3,265  
citations

230014

27  
h-index

252626

46  
g-index

187  
all docs

187  
docs citations

187  
times ranked

4205  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. <i>Heart</i> , 2022, 108, 458-466.	1.2	28
2	Impact of Different Measures of Body Size on the Radiation Dose During Coronary Angiography and Percutaneous Coronary Intervention: Results from a Large Single Center Cohort. <i>Angiology</i> , 2022, 73, 478-484.	0.8	0
3	Impact of 719Trp>Arg Polymorphism of KIF 6 Gene on Contrast Induced Nephropathy in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention. <i>Global Heart</i> , 2022, 17, 16.	0.9	1
4	Relationship between vitamin D and cholesterol levels in STEMI patients undergoing primary percutaneous coronary intervention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 957-964.	1.1	3
5	Short-term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new-generation drug-eluting stent. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3530.	1.7	4
6	Psychological burden of the COVID-19 pandemic 6 months after the outbreak – the voice of the young doctors’ generation: An international survey. <i>Kardiologia Polska</i> , 2022, 80, 485-488.	0.3	0
7	P97 – VALIDATION OF THE ACADEMIC RESEARCH CONSORTIUM HIGH BLEEDING RISK CRITERIA IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW AND METANALYSIS OF 10 STUDIES AND 67,862 PATIENTS. <i>European Heart Journal Supplements</i> , 2022, 24, .	0.0	0
8	Updates on the Management of STEMI in 2021. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2245-2246.	1.2	1
9	Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, 74, 140-148.	0.4	5
10	Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 43-49.	0.6	5
11	Potential role of hypovitaminosis D and vitamin D supplementation during COVID-19 pandemic. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 3-10.	0.2	19
12	Pharmacological therapy for the prevention of cardiovascular events in patients with myocardial infarction with non-obstructed coronary arteries (MINOCA): Insights from a multicentre national registry. <i>International Journal of Cardiology</i> , 2021, 327, 9-14.	0.8	37
13	Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1276-1285.	1.1	1
14	Impact of uric acid on immature platelet fraction in patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2021, 198, 171-181.	0.8	1
15	Determinants of vitamin D activation in patients with acute coronary syndromes and its correlation with inflammatory markers. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 36-43.	1.1	15
16	Cholecalciferol levels, inflammation and leukocytes parameters: Results from a large single-centre cohort of patients. <i>Clinical Nutrition</i> , 2021, 40, 2228-2236.	2.3	5
17	Prognostic impact of Vitamin D deficiency in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>European Journal of Internal Medicine</i> , 2021, 83, 62-67.	1.0	12
18	Association of lower vitamin D levels with inflammation and leucocytes parameters in patients with and without diabetes mellitus undergoing coronary angiography. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13439.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Impact of Age on the Functional Evaluation of Intermediate Coronary Stenoses With Instantaneous Wave-Free Ratio and Fractional Flow Reserve. <i>Angiology</i> , 2021, 72, 62-69.	0.8	6
20	Impact of aging on the effects of intracoronary adenosine, peak hyperemia and its duration during fractional flow reserve assessment. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 625-631.	0.3	3
21	Low hemoglobin predicts high platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1309-1316.	0.7	6
22	Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 523-531.	1.0	13
23	Impact of the Polymorphism rs5751876 of the Purinergic Receptor ADORA2A on Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 137-145.	0.9	1
24	Tratamiento antiagregante de muy corta duración tras la ICP y nuevos SLF: metanálisis de 5 estudios aleatorizados. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 140-148.	0.6	14
25	Preprocedural $\beta$ -Blockers in the Functional Assessment of Intermediate Coronary Lesions by Instantaneous Wave-Free Ratio. <i>Angiology</i> , 2021, 72, 687-692.	0.8	3
26	Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. <i>Atherosclerosis</i> , 2021, 321, 39-44.	0.4	6
27	Gender differences with short-term vs 12-months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 797-807.	1.0	6
28	Reply Letter to: "The Diagnostic Accuracy of the Instantaneous Wave-Free Ratio". <i>Angiology</i> , 2021, 72, 694-695.	0.8	0
29	Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. <i>Vascular Pharmacology</i> , 2021, 137, 106828.	1.0	4
30	Comments on "Sex differences in distribution, management and outcomes of combined ischemic bleeding risk following acute coronary syndrome". <i>International Journal of Cardiology</i> , 2021, 331, 8-9.	0.8	0
31	A "shark"-masked electrocardiogram: case report of a Tako-Tsubo syndrome. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab132.	0.3	4
32	Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials. <i>Vascular Pharmacology</i> , 2021, 138, 106859.	1.0	7
33	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111469.	2.5	3
34	Ticagrelor and prasugrel in acute coronary syndrome: a single-arm crossover platelet reactivity study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 686-692.	0.6	3
35	Antiplatelet therapy in ACS elderly patients: Another piece of this intriguing puzzle. <i>International Journal of Cardiology</i> , 2021, 334, 28-29.	0.8	0
36	Impact of sex on the functional assessment of intermediate coronary lesions by instantaneous wave-free ratio. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	1

#	ARTICLE	IF	CITATIONS
37	El peligro de los metanálisis. Respuesta. Revista Espanola De Cardiologia, 2021, 74, 817-818.	0.6	0
38	The danger of meta-analyses. Response. Revista Espanola De Cardiologia (English Ed ), 2021, 74, 817-818.	0.4	0
39	Reply to: "Mortality and in-stent thrombosis in COVID-19 patients with STEMI: More work ahead" Atherosclerosis, 2021, 336, 49-50.	0.4	0
40	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. Atherosclerosis, 2021, 332, 48-54.	0.4	28
41	Commentary to: "Prognosis of spontaneous myocardial infarction and various definitions of periprocedural myocardial infarction in patients who underwent percutaneous coronary intervention" International Journal of Cardiology, 2021, 340, 14-16.	0.8	0
42	Vitamin D deficiency is associated with impaired reperfusion in STEMI patients undergoing primary percutaneous coronary intervention. Vascular Pharmacology, 2021, 140, 106897.	1.0	6
43	Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic. Diabetes Epidemiology and Management, 2021, 4, 100022.	0.4	1
44	The FAST-STEMI Network in Biella From 2013 to 2019: Impact of the Delocalization of the Hospital Facilities on Ischemia Time and In-hospital Outcomes. Critical Pathways in Cardiology, 2021, 20, 75-80.	0.2	2
45	Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome. Journal of Geriatric Cardiology, 2021, 18, 210-218.	0.2	1
46	Predictors of Mortality and Long-Term Outcome in Patients with Anterior STEMI: Results from a Single Center Study. Journal of Clinical Medicine, 2021, 10, 5634.	1.0	5
47	Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 292-299.	1.1	12
48	Polymer-Free vs. Polymer-Coated Drug-Eluting Stents for the Treatment of Coronary Artery Disease: A Meta-Analysis of 16 Randomized Trials. Cardiovascular Revascularization Medicine, 2020, 21, 745-753.	0.3	10
49	Impact of active smoking on the immature platelet fraction and its relationship with the extent of coronary artery disease. European Journal of Clinical Investigation, 2020, 50, e13181.	1.7	12
50	Benefits of short-term or prolonged as compared to standard 1-year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials. Journal of Thrombosis and Thrombolysis, 2020, 50, 337-354.	1.0	7
51	Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials. Catheterization and Cardiovascular Interventions, 2020, 96, 813-824.	0.7	5
52	Noninvasive Imaging Risk Stratification with Computed Tomography Angiography for Coronary Artery Disease. Cardiology Clinics, 2020, 38, 543-550.	0.9	7
53	Vitamin D levels condition the outcome benefits of renin-angiotensin system inhibitors (RASi) among patients undergoing percutaneous coronary intervention. Pharmacological Research, 2020, 160, 105158.	3.1	4
54	Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor. Vascular Pharmacology, 2020, 132, 106765.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor. <i>Thrombosis Research</i> , 2020, 196, 231-237.	0.8	5
56	Low vitamin D levels affect left ventricular wall thickness in severe aortic stenosis. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 905-911.	0.6	4
57	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2321-2330.	1.2	154
58	Relationship between adenosine A2a receptor polymorphism rs5751876 and fractional flow reserve during percutaneous coronary intervention. <i>Heart and Vessels</i> , 2020, 35, 1349-1359.	0.5	2
59	Impact of diabetes on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: insights from the ELDERLY ACS 2 trial. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 453-459.	0.6	13
60	Impact of gender on immature platelet count and its relationship with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 511-521.	1.0	4
61	Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1144-1149.	0.3	5
62	Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 730-737.	1.1	4
63	Impact of diabetes mellitus on immature platelet fraction and its association with coronary artery disease. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3290.	1.7	2
64	Impact of aging on immature platelet count and its relationship with coronary artery disease. <i>Platelets</i> , 2020, 31, 1060-1068.	1.1	6
65	Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-12.	1.1	5
66	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 215.	2.7	30
67	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020, 27, 661-676.	0.5	7
68	Polymorphism rs2762939 of CYP24A1 enzyme and coronary artery disease: angiographic results from a large prospective cohort of patients. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 366-371.	0.5	1
69	Advanced age, time to treatment and long-term mortality: single centre data from the FAST-STEMI network. <i>Medical Research Journal</i> , 2020, 5, 135-140.	0.1	1
70	Incidental Diagnosis After a Car Accident. <i>JACC: Case Reports</i> , 2020, 2, 2289-2294.	0.3	1
71	Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease. <i>Platelets</i> , 2019, 30, 615-623.	1.1	13
72	Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. <i>Vascular Pharmacology</i> , 2019, 120, 106564.	1.0	12

#	ARTICLE	IF	CITATIONS
73	Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 413-421.	1.0	7
74	Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials. <i>Atherosclerosis</i> , 2019, 284, 136-147.	0.4	11
75	Impact of long-term therapy with acetylsalicylic acid on immature platelet count. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 306-312.	0.6	3
76	Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment. <i>Platelets</i> , 2019, 30, 915-922.	1.1	3
77	Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019, 275, 48-52.	0.8	9
78	Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. <i>Journal of Cardiology</i> , 2019, 73, 198-203.	0.8	11
79	Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment. <i>International Journal of Cardiology</i> , 2019, 284, 16-21.	0.8	7
80	Statins and Elderly: From Clinical Trials to Daily Practice. <i>Current Vascular Pharmacology</i> , 2019, 17, 233-238.	0.8	3
81	Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). <i>EuroIntervention</i> , 2019, 15, e990-e998.	1.4	122
82	Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. <i>Pharmacological Research</i> , 2018, 129, 27-33.	3.1	18
83	Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. <i>Thrombosis Research</i> , 2018, 164, 17-23.	0.8	9
84	Percutaneous Versus Surgical Revascularization for Left Main or Multivessel Coronary Artery Disease: Results From a Large-Scale Meta-Analysis in the Era of Drug-Eluting Stents. <i>Angiology</i> , 2018, 69, 812-824.	0.8	13
85	Vitamin D deficiency and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 744-750.	0.3	3
86	Antithrombotic Therapy After Percutaneous Aortic Valve Implantation: Large Gaps for a Matter of Extreme Importance. <i>Response. Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 309.	0.4	0
87	Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity. <i>Angiology</i> , 2018, 69, 490-496.	0.8	12
88	Resting P d/P a and haemodynamic relevance of coronary stenosis as evaluated by fractional flow reserve. <i>Coronary Artery Disease</i> , 2018, 29, 138-144.	0.3	7
89	Antiagregaci3n doble frente a simple, con o sin anticoagulaci3n, tras reemplazo percut3neo de v3lvula a3rtica: comparaci3n indirecta y metan3lisis. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 257-266.	0.6	13
90	Impact of statin therapy on the immature platelet count in patients with coronary artery disease: A single centre cohort study. <i>International Journal of Cardiology</i> , 2018, 272, 40-44.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials. <i>International Journal of Cardiology</i> , 2018, 264, 30-38.	0.8	20
92	Comments on "Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature" <i>International Journal of Cardiology</i> , 2018, 266, 38-39.	0.8	3
93	Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. <i>Thrombosis Research</i> , 2017, 150, 90-95.	0.8	25
94	Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 553-565.	0.7	0
95	Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Vascular Pharmacology</i> , 2017, 93-95, 42-47.	1.0	10
96	Immature platelet fraction and the extent of coronary artery disease: A single centre study. <i>Atherosclerosis</i> , 2017, 260, 110-115.	0.4	10
97	Impact of polymorphism rs7041 and rs4588 of Vitamin D Binding Protein on the extent of coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 775-783.	1.1	21
98	Gender Difference in the Risk of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention. <i>Angiology</i> , 2017, 68, 542-546.	0.8	20
99	Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta- Analysis of Randomized Trials. <i>Current Vascular Pharmacology</i> , 2017, 16, 79-92.	0.8	17
100	Optical coherence tomography guidance during bioresorbable vascular scaffold implantation. <i>Journal of Thoracic Disease</i> , 2017, 9, S986-S993.	0.6	5
101	Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. <i>Platelets</i> , 2016, 27, 1-12.	1.1	5
102	An anomalous case of acute coronary syndrome. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e118-e121.	0.6	1
103	Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 567-574.	1.1	9
104	Bivalirudin Versus Unfractionated Heparin in Acute Coronary Syndromes: An Updated Meta-analysis of Randomized Trials. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 732-745.	0.4	8
105	Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. <i>American Heart Journal</i> , 2016, 178, 37-44.	1.2	20
106	Impact of renal function on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. <i>Thrombosis Research</i> , 2016, 141, 139-144.	0.8	16
107	Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. <i>Thrombosis Research</i> , 2016, 143, 45-49.	0.8	23
108	Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 245-253.	1.0	26

#	ARTICLE	IF	CITATIONS
109	Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography. <i>Atherosclerosis</i> , 2016, 250, 114-121.	0.4	25
110	Impact of neutrophil-to-lymphocyte ratio on periprocedural myocardial infarction in patients undergoing non-urgent percutaneous coronary revascularisation. <i>Netherlands Heart Journal</i> , 2016, 24, 462-474.	0.3	19
111	Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Platelets</i> , 2016, 27, 576-582.	1.1	28
112	Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 611-622.	1.3	8
113	Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. <i>Cardiovascular Therapeutics</i> , 2016, 34, 209-215.	1.1	9
114	Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1486-1487.	1.9	4
115	Bivalirudina frente a heparina no fraccionada en síndromes coronarios agudos: un meta-análisis actualizado de ensayos aleatorizados. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 732-745.	0.6	14
116	Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. <i>Vascular Pharmacology</i> , 2016, 77, 48-53.	1.0	23
117	Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 352-358.	1.1	20
118	Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 57-64.	1.9	57
119	Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 143-150.	1.3	22
120	Impact of Diabetes on Homocysteine Levels and Its Relationship with Coronary Artery Disease: A Single-Centre Cohort Study. <i>Annals of Nutrition and Metabolism</i> , 2016, 68, 180-188.	1.0	12
121	Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Vascular Pharmacology</i> , 2016, 79, 11-15.	1.0	22
122	Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 931-937.	0.8	30
123	Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols. <i>Vascular Pharmacology</i> , 2016, 80, 43-49.	1.0	7
124	Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 663-670.	1.0	21
125	Optimal Duration of Dual Antiplatelet Therapy After DES Implantation. <i>Angiology</i> , 2016, 67, 224-238.	0.8	26
126	Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease. <i>Angiology</i> , 2016, 67, 75-82.	0.8	74



#	ARTICLE	IF	CITATIONS
127	Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 364-370.	0.8	25
128	Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 35-40.	0.8	15
129	Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies. <i>Platelets</i> , 2015, 26, 530-535.	1.1	4
130	Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. <i>Diabetes and Metabolism</i> , 2015, 41, 304-311.	1.4	71
131	Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 464-470.	1.1	100
132	Impact of age on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. <i>Experimental Gerontology</i> , 2015, 62, 32-36.	1.2	28
133	Impact of red blood cells count and high density lipoproteins with the prevalence and extent of coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 61-68.	1.0	9
134	The Inconclusive Results of the Studies on Glycoprotein IIIa Platelet Receptor Gene Polymorphism and Coronary Artery Disease. <i>Angiology</i> , 2015, 66, 88-89.	0.8	0
135	Elevated Homocysteine and the Risk of Contrast-Induced Nephropathy. <i>Angiology</i> , 2015, 66, 333-338.	0.8	14
136	Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study. <i>Atherosclerosis</i> , 2015, 241, 241-248.	0.4	57
137	Glycosylated hemoglobin and the risk of periprocedural myocardial infarction in non-diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 517-522.	1.2	5
138	Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials. <i>Thrombosis Research</i> , 2015, 135, 902-915.	0.8	17
139	Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 100-105.	0.6	5
140	Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. <i>Atherosclerosis</i> , 2015, 243, 389-394.	0.4	11
141	Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 443-450.	1.3	6
142	Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1739-1747.	0.9	18
143	Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: A single-centre study. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 541-550.	1.1	4
144	Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 181-186.	1.1	35

#	ARTICLE	IF	CITATIONS
145	Absolute eosinophils count and the extent of coronary artery disease: a single centre cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 459-466.	1.0	21
146	Platelet- $\alpha$ IIb/3a receptor ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. <i>Heart and Vessels</i> , 2015, 30, 20-27.	0.5	8
147	Relationship Between Glycoprotein IIIa Platelet Receptor Gene Polymorphism and Coronary Artery Disease. <i>Angiology</i> , 2015, 66, 79-85.	0.8	8
148	Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 9-23.	1.1	29
149	Effect of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 85-92.	1.7	5
150	High-Density Lipoproteins and Coronary Artery Disease. <i>Angiology</i> , 2014, 65, 696-702.	0.8	11
151	Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 458-464.	1.1	18
152	Platelet HPA-1 $\alpha$ /HPA-1 $\beta$ polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI. <i>Platelets</i> , 2014, 25, 367-372.	1.1	9
153	Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 297-304.	1.7	6
154	Vitamin D deficiency is independently associated with the extent of coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 634-642.	1.7	83
155	Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 339-350.	0.8	64
156	Haemoglobin levels do not correlate with the extent of coronary artery disease. <i>Coronary Artery Disease</i> , 2014, 25, 463-468.	0.3	2
157	Combination between mean platelet volume and platelet distribution width to predict the prevalence and extent of coronary artery disease. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 86-91.	0.5	29
158	Meta-analysis of 14 trials comparing bypass grafting vs drug-eluting stents in diabetic patients with multivessel coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 344-354.	1.1	38
159	Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 345-352.	1.0	12
160	Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: A single-centre cohort study. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 640-646.	1.5	25
161	Eosinophils count and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions. <i>Atherosclerosis</i> , 2014, 236, 169-174.	0.4	8
162	Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 388-394.	1.0	15

#	ARTICLE	IF	CITATIONS
163	The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 493-502.	1.0	21
164	Glycosylated Hemoglobin and Coronary Artery Disease in Patients Without Diabetes Mellitus. <i>American Journal of Preventive Medicine</i> , 2014, 47, 9-16.	1.6	29
165	MTHFR polymorphism and risk of periprocedural myocardial infarction after coronary stenting. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 532-537.	1.1	7
166	Diabetes, glucose control and mean platelet volume: a single-centre cohort study. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 288-294.	1.1	31
167	Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. <i>Thrombosis Research</i> , 2014, 134, 288-293.	0.8	88
168	Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 107-113.	0.5	7
169	Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty. <i>Atherosclerosis</i> , 2013, 228, 136-141.	0.4	22
170	Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the DESERT cooperation. <i>Atherosclerosis</i> , 2013, 230, 12-16.	0.4	15
171	Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. <i>International Journal of Cardiology</i> , 2013, 167, 561-563.	0.8	35
172	Relation of Gender to Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. <i>American Journal of Cardiology</i> , 2013, 111, 936-940.	0.7	25
173	PIA1/PIA2 polymorphism does not influence response to Gp IIb/IIIa inhibitors in patients undergoing coronary angioplasty. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 411-418.	0.5	33
174	Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 619-624.	0.5	57
175	Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 756-759.	0.5	28
176	Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials. <i>Atherosclerosis</i> , 2012, 222, 426-433.	0.4	75
177	Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 426-433.	1.1	103
178	Meta-Analysis of Randomized Trials of Glycoprotein IIb/IIIa Inhibitors in High-Risk Acute Coronary Syndromes Patients Undergoing Invasive Strategy. <i>American Journal of Cardiology</i> , 2011, 107, 198-203.	0.7	56
179	High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 458-463.	1.0	58
180	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 561-569.	0.2	34

#	ARTICLE	IF	CITATIONS
181	Thrombectomy During Primary Angioplasty: Methods, Devices, and Clinical Trial Data. Current Cardiology Reports, 2010, 12, 422-428.	1.3	6
182	Platelet distribution width and the extent of coronary artery disease: Results from a large prospective study. Platelets, 2010, 21, 508-514.	1.1	103
183	Evaluation and management of special subgroups after primary percutaneous coronary intervention. American Heart Journal, 2010, 160, S22-S27.	1.2	11
184	Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty. Thrombosis and Haemostasis, 2009, 102, 428-436.	1.8	83